Trials / Terminated
TerminatedNCT01050218
Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
A 9-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 237 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to learn if long-term treatment with DVS SR is safe for treating the pain and other symptoms associated with diabetic peripheral neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desvenlafaxine Succinate Sustained-Release (DVS SR) |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2010-01-15
- Last updated
- 2023-12-11
- Results posted
- 2010-05-11
Source: ClinicalTrials.gov record NCT01050218. Inclusion in this directory is not an endorsement.